R. Balena

3.0k total citations
47 papers, 2.4k citations indexed

About

R. Balena is a scholar working on Molecular Biology, Orthopedics and Sports Medicine and Oncology. According to data from OpenAlex, R. Balena has authored 47 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Molecular Biology, 23 papers in Orthopedics and Sports Medicine and 21 papers in Oncology. Recurrent topics in R. Balena's work include Bone health and osteoporosis research (23 papers), Bone health and treatments (21 papers) and Bone Metabolism and Diseases (14 papers). R. Balena is often cited by papers focused on Bone health and osteoporosis research (23 papers), Bone health and treatments (21 papers) and Bone Metabolism and Diseases (14 papers). R. Balena collaborates with scholars based in United States, Switzerland and United Kingdom. R. Balena's co-authors include Gideon A. Rodan, J.G. Seedor, P. Masarachia, Mark Boldrin, A. Markatos, Miron Weinreb, Pierre D. Delmas, M. Shea, Christoph Kapitza and Hilton J. Klein and has published in prestigious journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and The Journal of Clinical Endocrinology & Metabolism.

In The Last Decade

R. Balena

47 papers receiving 2.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
R. Balena United States 26 1.1k 1.1k 964 737 461 47 2.4k
Ann E. Kearns United States 23 839 0.7× 759 0.7× 831 0.9× 167 0.2× 435 0.9× 55 2.2k
Torben Harsløf Denmark 25 761 0.7× 548 0.5× 693 0.7× 342 0.5× 345 0.7× 81 1.8k
S. C. Manolagas United States 10 786 0.7× 837 0.8× 1.3k 1.3× 186 0.3× 140 0.3× 14 2.2k
Zhaopo Geng United States 22 978 0.9× 1.2k 1.1× 1.6k 1.6× 327 0.4× 195 0.4× 28 2.8k
Ulrike I. Mödder United States 21 741 0.7× 584 0.5× 936 1.0× 189 0.3× 215 0.5× 24 1.9k
Miriam Cintrón United States 11 905 0.8× 498 0.4× 767 0.8× 315 0.4× 241 0.5× 13 1.6k
Göran Andersson Sweden 26 343 0.3× 658 0.6× 1.3k 1.3× 284 0.4× 187 0.4× 67 2.0k
Christian Rosenquist Denmark 13 437 0.4× 496 0.4× 420 0.4× 218 0.3× 146 0.3× 17 1.5k
Dennis B. Henriksen Denmark 16 522 0.5× 470 0.4× 621 0.6× 465 0.6× 267 0.6× 25 1.6k
Linda R. Halstead United States 23 505 0.4× 532 0.5× 833 0.9× 340 0.5× 174 0.4× 38 2.2k

Countries citing papers authored by R. Balena

Since Specialization
Citations

This map shows the geographic impact of R. Balena's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R. Balena with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R. Balena more than expected).

Fields of papers citing papers by R. Balena

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by R. Balena. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R. Balena. The network helps show where R. Balena may publish in the future.

Co-authorship network of co-authors of R. Balena

This figure shows the co-authorship network connecting the top 25 collaborators of R. Balena. A scholar is included among the top collaborators of R. Balena based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with R. Balena. R. Balena is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hollander, Priscilla, Ben Lasko, Anthony Barnett, et al.. (2013). Effects of taspoglutide on glycemic control and body weight in obese patients with type 2 diabetes (T‐emerge 7 study). Obesity. 21(2). 238–247. 25 indexed citations
2.
Balena, R., et al.. (2012). Combination therapy with GLP ‐1 receptor agonists and basal insulin: a systematic review of the literature. Diabetes Obesity and Metabolism. 15(6). 485–502. 116 indexed citations
3.
Henry, Robert R., et al.. (2012). Efficacy and Safety of Taspoglutide in Patients with Type 2 Diabetes Inadequately Controlled with Metformin Plus Pioglitazone over 24 Weeks: T-Emerge 3 Trial. The Journal of Clinical Endocrinology & Metabolism. 97(7). 2370–2379. 23 indexed citations
4.
Ratner, Robert E., Michael A. Nauck, Christoph Kapitza, et al.. (2010). Safety and tolerability of high doses of taspoglutide, a once‐weekly human GLP‐1 analogue, in diabetic patients treated with metformin: a randomized double‐blind placebo‐controlled study1,2. Diabetic Medicine. 27(5). 556–562. 37 indexed citations
5.
6.
Herd, R. J. M., et al.. (2000). Cyclical Etidronate Therapy for Prevention of Postmenopausal Bone Loss: A 1-Year Open-Label Follow-Up Study. Calcified Tissue International. 66(5). 348–354. 3 indexed citations
7.
Heath, David A., et al.. (2000). The Effects of Cyclical Etidronate on Early Postmenopausal Bone Loss. Journal of Clinical Densitometry. 3(1). 27–33. 9 indexed citations
8.
Adámi, S., Vincenzina Bruni, Angelamaria Becorpi, et al.. (2000). Prevention of early postmenopausal bone loss with cyclical etidronate. Journal of Endocrinological Investigation. 23(5). 310–316. 13 indexed citations
9.
Balena, R., Michael Kleerekoper, J. Földes, et al.. (1998). Effects of Different Regimens of Sodium Fluoride Treatment for Osteoporosis on the Structure, Remodeling and Mineralization of Bone. Osteoporosis International. 8(5). 428–435. 28 indexed citations
10.
Balena, R., et al.. (1997). The Prevention of Early Postmenopausal Bone Loss by Cyclical Etidronate Therapy. The American Journal of Medicine. 103(2). 92–99. 56 indexed citations
11.
Delmas, Pierre D., et al.. (1997). Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study.. Journal of Clinical Oncology. 15(3). 955–962. 223 indexed citations
12.
Masarachia, P., Miron Weinreb, R. Balena, & Gideon A. Rodan. (1996). Comparison of the distribution of 3H-alendronate and 3H-Etidronate in rat and mouse bones. Bone. 19(3). 281–290. 205 indexed citations
13.
Zegels, Brigitte, et al.. (1995). Effect of risedronate on collagen cross-links in postmenopausal osteoporosis. Open Repository and Bibliography (University of Liège). 2 indexed citations
14.
Rosen, Harold N., Steven R. Tollin, R. Balena, et al.. (1995). Differentiating between orchiectomized rats and controls using measurements of trabecular bone density: A comparison among DXA, Histomorphometry, and peripheral quantitative computerized tomography. Calcified Tissue International. 57(1). 35–39. 75 indexed citations
15.
Harada, Shun-ichi, R. Balena, Gideon A. Rodan, & Sevgi B. Rodan. (1995). The Role of Prostaglandins in Bone Formation. Connective Tissue Research. 31(4). 279–282. 28 indexed citations
16.
Yamamoto, Michiko, A. Markatos, J.G. Seedor, et al.. (1993). The effects of the aminobisphosphonate alendronate on thyroid hormone-induced osteopenia in rats. Calcified Tissue International. 53(4). 278–282. 26 indexed citations
17.
Rodan, Gideon A., J.G. Seedor, & R. Balena. (1993). Preclinical pharmacology of alendronate. Osteoporosis International. 3(S3). 7–12. 63 indexed citations
18.
Rodan, Gideon A. & R. Balena. (1993). Bisphosphonates in the Treatment of Metabolic Bone Diseases. Annals of Medicine. 25(4). 373–378. 46 indexed citations
19.
Balena, R., A. Markatos, Michael A. Gentile, et al.. (1993). The aminobisphosphonate alendronate inhibits bone loss induced by thyroid hormone in the rat comparison between effects on tibiae and vertebrae. Bone. 14(3). 499–504. 22 indexed citations
20.
Balena, R., Brian C. Toolan, M. Shea, et al.. (1993). The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates.. Journal of Clinical Investigation. 92(6). 2577–2586. 316 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ann E. Kearns Breakdown of academic impact, for papers by Torben Harsløf Breakdown of academic impact, for papers by S. C. Manolagas Breakdown of academic impact, for papers by Zhaopo Geng Breakdown of academic impact, for papers by Ulrike I. Mödder Breakdown of academic impact, for papers by Miriam Cintrón Breakdown of academic impact, for papers by Göran Andersson Breakdown of academic impact, for papers by Christian Rosenquist Breakdown of academic impact, for papers by Dennis B. Henriksen Breakdown of academic impact, for papers by Linda R. Halstead
Rankless by CCL
2026